Skip to content

Search

'Natural killers' potential new cancer weapon

The Cancer Immunology team at The Kids is investigating how the body's 'natural killer' cells can be harnessed to fight cancer – whilst also protecting kids from nasty chemotherapy side effects.

NHMRC funding boost to child health research

The Kids researchers will use nearly $8.5 million awarded by the National Health and Medical Research Council (NHMRC) to tackle health issues including respiratory disease, brain cancer, vaccination and Aboriginal health.

The Kids researchers share in $1.75m ACRF grant for cancer research

Three The Kids researchers are collaborating on a cancer research project that has been awarded a $1.75mill grant by the Australian Cancer Research Fund.

Kids cancer champion nominated for WA Australian of the Year

Dr Nick Gottardo, Co-Head of The Kids Research Institute Australia's Brain Tumour Research Team, has been announced a nominee for the 2018 WA Australian of the Year Award

WA children with most aggressive cancers to benefit from Australian-first personalised medicine clinical trial

Personalised medicine for childhood cancers in West Australia is a step closer thanks to the Zero Childhood Cancer program’s state clinical trial launched today

Ependymoma Awareness Day

Ethan was not even two when he was diagnosed with a rare type of brain tumour known as an ependymoma.

Experts Pledge Global Assault on Kids’ Cancer

A global plan to tackle one of the most aggressive types of childhood brain tumours will be developed as a result of a meeting of international experts in WA.

Insights into the Clinical, Biological and Therapeutic Impact of Copy Number Alteration in Cancer

Copy number alterations (CNAs), resulting from the gain or loss of genetic material from as little as 50 base pairs or as big as entire chromosome(s), have been associated with many congenital diseases, de novo syndromes and cancer. It is established that CNAs disturb the dosage of genomic regions including enhancers/promoters, long non-coding RNA and gene(s) among others, ultimately leading to an altered balance of key cellular functions.

The critical role of the bone marrow stromal microenvironment for the development of drug screening platforms in leukemia

Extensive research over the past 50 years has resulted in significant improvements in survival for patients diagnosed with leukemia. Despite this, a subgroup of patients harboring high-risk genetic alterations still suffer from poor outcomes. There is a desperate need for new treatments to improve survival, yet consistent failure exists in the translation of in vitro drug development to clinical application.

Pharmacokinetics of PEGasparaginase in Infants with Acute Lymphoblastic Leukemia

PEGasparaginase is known to be a critical drug for treating pediatric acute lymphoblastic leukemia (ALL), however, there is insufficient evidence to determine the optimal dose for infants who are less than one year of age at diagnosis. This international study was conducted to identify the pharmacokinetics of PEGasparaginase in infants with newly diagnosed ALL and gather insight into the clearance and dosing of this population.